| Oct 28 |
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal
|
| Oct 28 |
Novartis’ Fabhalta shows positive outcomes in C3 glomerulopathy treatment
|
| Oct 26 |
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
|
| Oct 25 |
NVS vs. LLY: Which Stock Is the Better Value Option?
|
| Oct 25 |
Stocks to watch next week: BP, Shell, Uber, HSBC and Intel
|
| Oct 25 |
What To Expect When Novartis Reports Q3 2024 Results
|
| Oct 24 |
Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics
|
| Oct 24 |
3 Absurdly Cheap Stocks That Pay High Dividends
|
| Oct 24 |
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
|
| Oct 24 |
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
|
